XW0V3WA
Introduction Bones to New Technology Group 10 with AGN1 Bone Void Filler, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | V Bones |
| Approach | 3 Percutaneous |
| Device | W AGN1 Bone Void Filler |
| Qualifier | A New Technology Group 10 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Bones
Bones as the target of a New Technology introduction procedure typically involves placing a novel osteobiologic, antimicrobial, or regenerative substance directly into osseous tissue, for example to combat resistant osteomyelitis or promote healing in a nonunion fracture. Bone's dense, mineralized structure limits diffusion of systemically administered drugs, which is precisely why local introduction into the bone itself is chosen when a targeted concentration at the site of disease is needed. Because this code applies to bones as a general category rather than one named bone, the operative documentation should make clear that the substance was delivered into osseous tissue broadly, and identify the specific New Technology agent used. Accurate coding here helps distinguish investigational bone-directed therapies from established graft or antibiotic bead procedures already captured elsewhere in ICD-10-PCS.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: AGN1 Bone Void Filler
AGN1 Bone Void Filler identifies use of a specific calcium sulfate/calcium phosphate composite bone graft substitute designed to resorb and be replaced by new bone as it fills a skeletal void, sometimes also carrying antimicrobial properties. It is distinguished from the peptide-enhanced and antibiotic-eluting fillers by referring to a named proprietary composite material rather than a generic functional category.
Qualifier: New Technology Group 10
New Technology Group 10 flags a procedure as part of the 2023 batch of add-on codes recognized under the New Technology section. The value itself carries no information about the device or drug involved; that comes from the table, body part, and approach values alongside it. Coders should not confuse it with Group 9 or Group 11, which cover the cohorts approved in the years immediately before and after.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.